Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Enzyme replacement therapy (pegylated recombinant alpha-galactosidase A)

Pegunigalsidase alfa

ELFABRIO

Dosage form
Tablet
Available strengths
2 mg/mL
Drug class
Enzyme replacement therapy (pegylated recombinant alpha-galactosidase A)
Common brand
ELFABRIO

Clinical overview. Pegunigalsidase alfa is a pegylated enzyme replacement therapy (brand name ELFABRIO) given by intravenous infusion every other week to treat Fabry disease in adults. Infusion-associated reactions and mild cold-like or musculoskeletal symptoms are common, while severe hypersensitivity reactions, including anaphylaxis, and rare immune-mediated kidney inflammation are important risks that require medical supervision during infusions.

Indication

Common therapeutic uses

  • Pegunigalsidase alfa is used for the long-term treatment of adults with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency).

Pregnancy

Risk assessment and monitoring considerations

  • There are no available data on the use of pegunigalsidase alfa in pregnant women, and its use during pregnancy is not recommended.
  • Animal studies in pregnant rabbits showed maternal toxicity and embryo-fetal toxicity, including increased pregnancy loss and reduced fetal weight, at clinically relevant doses.
  • Pegunigalsidase alfa was shown to cross the placenta in pregnant rats, resulting in fetal exposure.
  • Health care providers should report any pregnancy occurring during treatment to the manufacturer's pregnancy safety program.

Breastfeeding

Infant exposure considerations

  • It is not known whether pegunigalsidase alfa passes into human breast milk, though animal studies have shown excretion into milk.
  • A risk to the breastfed infant cannot be excluded, so the benefits of breastfeeding should be weighed against the mother's need for treatment.

Geriatrics

Dosing and tolerability considerations

  • The safety and efficacy of pegunigalsidase alfa in patients over 65 have not been established, since clinical trials did not include this age group; caution is advised when prescribing to older adults.

Pediatrics

Use in children and adolescents

  • Pegunigalsidase alfa is not authorized for use in patients under 18 years of age, as no pediatric data are available to Health Canada.

Dosage & Administration

Practical dosing and administration

  • The recommended dose is 1 mg/kg of actual body weight, given by intravenous infusion every other week.
  • No specific dose adjustment is recommended for patients with renal or hepatic impairment.
  • For the initial 4 to 6 infusions, the infusion rate is based on body weight: 50 mL/h for patients under 70 kg, 83 mL/h for 70-100 kg, and 167 mL/h for patients over 100 kg; the rate may be increased in later infusions if tolerated.
  • Premedication with antihistamines, antipyretics, and/or corticosteroids may be considered before the first several infusions, particularly in patients switching from another enzyme replacement therapy or with a prior hypersensitivity reaction.
  • For a mild to moderate hypersensitivity or infusion-associated reaction, the infusion may be temporarily paused for 15 to 30 minutes and restarted at a slower rate; for a severe reaction, the infusion must be stopped immediately.
  • If symptoms subside after slowing or holding the infusion, it may be resumed at 25% to 50% of the rate at which the reaction occurred, then gradually increased if tolerated.
  • Treatment must be managed by a healthcare professional experienced in treating Fabry disease, with administration supervised at home, in clinic, or in hospital.
  • Vials should sit at room temperature for 15 to 30 minutes before use, and shaking or agitating the vial must be avoided to prevent foaming; an external heat source should never be used to warm it.
  • Other medications should not be infused through the same intravenous line as pegunigalsidase alfa, and an in-line 0.2 micron low protein-binding filter should be used for administration.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • There is no clinical trial experience with pegunigalsidase alfa overdose, so a specific overdose toxidrome has not been characterized.
  • Management of overdose is immediate supportive medical care with close observation of the patient's clinical status.

Common side effects

Frequently reported tolerability concerns

  • Nasopharyngitis (common cold-type symptoms) is very common.
  • Fatigue is very common.
  • Headache is very common.
  • Back pain is very common.
  • Cough is very common.
  • Diarrhea is very common.
  • Pain in the arms or legs is very common.
  • Nausea is very common.
  • Upper respiratory tract infection is very common.
  • Fever (pyrexia) is very common.
  • Sinusitis is very common.
  • Vomiting is common.
  • Chills are common.
  • Itching (pruritus) is common.
  • Dizziness is common.
  • Numbness or tingling (paresthesia) is common.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Severe hypersensitivity reactions, including anaphylaxis, have occurred, most often during the first infusion.
  • Infusion-associated reactions, including hypersensitivity, itching, nausea, dizziness, chills, and muscle pain, can occur during or shortly after an infusion.
  • A serious case of membranoproliferative glomerulonephritis (kidney inflammation from immune complex deposits) has been reported, causing a decline in kidney function that did not fully return to baseline after stopping treatment.
  • Antibodies against the drug can develop, particularly in patients switching from another enzyme replacement therapy, and may increase the risk of hypersensitivity and infusion reactions.
  • Seek urgent medical attention for signs of a severe allergic reaction, such as difficulty breathing, wheezing, swelling of the face or throat, or a sudden drop in blood pressure during or after an infusion.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients previously treated with another enzyme replacement therapy, since pre-existing antibodies may increase the risk of hypersensitivity and infusion-associated reactions.
  • Use with caution in patients with compromised cardiac function, who may be at higher risk of complications from infusion-associated reactions.
  • Use with caution and consider monitoring kidney function (serum creatinine and urine protein-to-creatinine ratio) if there is clinical concern about declining renal function.
  • Use with caution when driving or operating machinery, since dizziness and vertigo have been reported.
  • Use with caution and consider monitoring clinical or laboratory response (such as plasma lyso-Gb3 levels) when switching a patient from another enzyme replacement therapy to pegunigalsidase alfa.
  • Use with caution regarding fertility counseling, since the effects of pegunigalsidase alfa on human fertility have not been studied.
  • Appropriate medical support, including cardiopulmonary resuscitation equipment, should be readily available during every infusion given the risk of anaphylaxis.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to pegunigalsidase alfa or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.

Drug interactions

Clinically relevant combinations

  • No formal drug interaction studies have been conducted with pegunigalsidase alfa.
  • Interactions with other drugs have not been established.
  • Interactions with behavioural factors such as smoking, cannabis use, or alcohol consumption have not been studied.

Food interactions

Meal-related administration

  • No food interactions have been established for this intravenous infusion.

Time of administration

Practical scheduling

  • Administered by intravenous infusion every other week; timing is not tied to meals or time of day, though infusions should be scheduled with adequate time for pre-infusion preparation and post-infusion monitoring.

Storage

Product handling

  • Store vials in the refrigerator at 2°C to 8°C. Do not freeze.
  • Once diluted for infusion, the solution is stable for up to 24 hours refrigerated followed by up to 8 hours at room temperature, or up to 72 hours total if stored consistently at either condition; do not freeze or shake the diluted solution.

Patient take-away

Key counselling points for a quick closing summary

  • Pegunigalsidase alfa is a long-term enzyme replacement infusion given every other week to treat Fabry disease.
  • Because severe allergic reactions, including anaphylaxis, can occur, infusions are given under medical supervision with monitoring during and after each infusion.
  • Common effects include cold-like symptoms, fatigue, headache, and joint or limb pain, especially around the time of infusion.
  • Tell your healthcare professional right away about any signs of a severe allergic reaction, or any changes in urine output or unusual swelling that could suggest a kidney problem.

References

Source material and product information

  1. Health Canada Product Monograph — Pegunigalsidase alfa

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.